| scholarly article | Q13442814 |
| P2093 | author name string | Hao Liu | |
| Jing Wang | |||
| Bo Hu | |||
| Yanting Duan | |||
| Beifen Shen | |||
| Jiannan Feng | |||
| Chunxia Qiao | |||
| Ming Lv | |||
| Tingting Zhou | |||
| Xinying Li | |||
| Longlong Luo | |||
| P2860 | cites work | AXL Inhibitors in Cancer: A Medicinal Chemistry Perspective | Q38629669 |
| Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma | Q38835745 | ||
| ABL regulation by AXL promotes cisplatin resistance in esophageal cancer | Q39250660 | ||
| An anti-Axl monoclonal antibody attenuates xenograft tumor growth and enhances the effect of multiple anticancer therapies | Q39684120 | ||
| Axl as a potential therapeutic target in cancer: role of Axl in tumor growth, metastasis and angiogenesis | Q39820482 | ||
| Gas6 induces proliferation in prostate carcinoma cell lines expressing the Axl receptor. | Q40479676 | ||
| R428, a selective small molecule inhibitor of Axl kinase, blocks tumor spread and prolongs survival in models of metastatic breast cancer | Q43166849 | ||
| Clinical significance of AXL kinase family in gastric cancer | Q44095319 | ||
| Receptor tyrosine kinase AXL is induced by chemotherapy drugs and overexpression of AXL confers drug resistance in acute myeloid leukemia | Q46576090 | ||
| Axl and prostasin are biomarkers for prognosis of ovarian adenocarcinoma | Q46756754 | ||
| Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF/MEK inhibitors. | Q48243258 | ||
| The TAM family: phosphatidylserine sensing receptor tyrosine kinases gone awry in cancer. | Q54298179 | ||
| First Axl inhibitor enters clinical trials | Q85717127 | ||
| Structural basis for Gas6-Axl signalling. | Q24299209 | ||
| Axl receptor tyrosine kinase stimulated by the vitamin K-dependent protein encoded by growth-arrest-specific gene 6 | Q24313270 | ||
| Cell signaling by receptor tyrosine kinases | Q24598357 | ||
| LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models | Q27675641 | ||
| Identification of the product of growth arrest-specific gene 6 as a common ligand for Axl, Sky, and Mer receptor tyrosine kinases | Q28298018 | ||
| The E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cells. | Q33357894 | ||
| Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival | Q33667156 | ||
| A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors | Q34132936 | ||
| Direct regulation of GAS6/AXL signaling by HIF promotes renal metastasis through SRC and MET. | Q34217927 | ||
| Differential TAM receptor-ligand-phospholipid interactions delimit differential TAM bioactivities | Q34390266 | ||
| An engineered Axl 'decoy receptor' effectively silences the Gas6-Axl signaling axis | Q34439798 | ||
| Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma | Q35596369 | ||
| Kinetic exclusion assay technology: characterization of molecular interactions | Q36021387 | ||
| Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer | Q36128435 | ||
| Targeting Axl with an high-affinity inhibitory aptamer. | Q36460465 | ||
| The Axl receptor tyrosine kinase confers an adverse prognostic influence in pancreatic cancer and represents a new therapeutic target | Q37182283 | ||
| Preclinical validation of AXL receptor as a target for antibody-based pancreatic cancer immunotherapy | Q37321961 | ||
| Reduced Proteolytic Shedding of Receptor Tyrosine Kinases Is a Post-Translational Mechanism of Kinase Inhibitor Resistance | Q37380418 | ||
| The receptor tyrosine kinase Axl in cancer: biological functions and therapeutic implications. | Q38104686 | ||
| P4510 | describes a project that uses | ImageJ | Q1659584 |
| P433 | issue | 6 | |
| P1104 | number of pages | 9 | |
| P304 | page(s) | 5784-5792 | |
| P577 | publication date | 2019-04-15 | |
| P1433 | published in | Oncology Letters | Q20640514 |
| P1476 | title | Engineered AXL-ECD-Fc variants that abolish the AXL/Gas6 interaction suppress tumor cell migration | |
| P478 | volume | 17 |
| Q99579024 | Pharmaceutical inhibition of AXL suppresses tumor growth and invasion of esophageal squamous cell carcinoma | cites work | P2860 |
Search more.